Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
NCT ID: NCT00322517
Last Updated: 2011-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2006-04-30
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
NCT00078000
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
NCT00291577
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
NCT00051103
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
NCT00629148
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SU014813
SU014813
100 mg capsule/day for 6 cycle of 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SU014813
100 mg capsule/day for 6 cycle of 21 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have received prior treatment with an anthracycline and a taxane either concurrently or sequentially in the adjuvant and/or advanced disease treatment settings. Patients may have received as many as 2 other chemotherapy regimens in the advanced disease setting. Patients whose tumors are Her-2-positive must have received prior trastuzumab therapy. Prior hormonal therapy or immunotherapy in the adjuvant and/or advanced/metastatic disease settings is permitted. Prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease.
Exclusion Criteria
* Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months and should be asymptomatic
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
Santa Monica, California, United States
Pfizer Investigational Site
Valancia, California, United States
Pfizer Investigational Site
Corinth, Mississippi, United States
Pfizer Investigational Site
Southaven, Mississippi, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Magdeburg, , Germany
Pfizer Investigational Site
Marburg, , Germany
Pfizer Investigational Site
Chieti Scalo, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Mirano (VE), , Italy
Pfizer Investigational Site
Udine, , Italy
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Rotterdam, , Netherlands
Pfizer Investigational Site
Manchester, M20 4bx, United Kingdom
Pfizer Investigational Site
Sutton, Surrey, United Kingdom
Pfizer Investigational Site
Edinburgh, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6191007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.